Arsenic crosses the placenta and may have adverse consequences in utero and later in life. At present, little is known about arsenic concentrations in placenta and their relation to maternal and infant exposures particularly at common levels of exposure. We measured placenta arsenic in a US cohort potentially exposed via drinking water from private wells, and evaluated the relationships between placenta and maternal and infant biomarker arsenic concentrations. We measured total arsenic concentrations in placental samples from women enrolled in the New Hampshire Birth Cohort Study (N = 766). We compared these data to maternal urinary arsenic (total arsenic and individual species) collected at approximately 24-28 week gestation, along with maternal postpartum toenails and infant toenails using non-parametric multivariate analysis of log 10 -transformed data. We also examined the association between placental arsenic and household drinking water arsenic. Placenta arsenic concentrations were related to arsenic concentrations in maternal urine (β 0.55, P value o 0.0001), maternal (β 0.30, P value 0.0196) and infant toenails (β 0.40, P value 0.0293) and household drinking water (β 0.09, P value o0.0001). Thus, our data suggest that placenta arsenic concentrations reflect both maternal and infant exposures.
INTRODUCTION
Arsenic readily crosses the placenta, and may adversely affect fetal development. 1 Early life exposure to arsenic has also been linked to adverse health effects later in life. These include an increased risk of lower respiratory tract infection in children 2, 3 and higher risk of cancer in both animal models and from emerging epidemiological studies of highly exposed populations. 2, [4] [5] [6] [7] The biological and health effects of low-dose arsenic exposure are poorly understood and, in some studies, contrast with effects seen at higher doses, suggesting a complex dose-response relationship. 8 Moreover, populations may experience differences in their underlying risk of disease and lifestyle factors such as dietary habits, which may play a role in susceptibility to arsenicinduced health effects, by influencing arsenic metabolism. [9] [10] [11] The placenta has critical functions in nutrient and waste transport between the mother and fetus and in hormonally regulating the progression of pregnancy, and may be vulnerable to the impacts of arsenic. 12 Despite the non-invasive nature of placental tissue collection, and early observations that placental metal levels correlated with those measured in maternal and fetal blood, 13, 14 the potential of the placenta as a pregnancy biomarker 15 has not been fully realized. Recently, placenta has been used to identify early effects of exposure to numerous environmental contaminant metals and metalloids, including lead, mercury and cadmium, 5 but studies on arsenic are lacking. Even in highly exposed populations, arsenic concentrations are in the ng/g range, 16 which present technical challenges for accurate measurement. As a result, there are very few epidemiological studies of arsenic in placenta. Therefore, we used sensitive inductively coupled plasma mass spectrometry (ICP-MS) methods to determine whether placenta arsenic concentrations were related to drinking water arsenic and other biomarkers of arsenic exposure in a US birth cohort with a range of concentrations from private well water.
METHODS
The study protocols for the New Hampshire Birth Cohort Study (NHBCS) were approved by the Committee for the Protection of Human Subjects at Dartmouth College. All study participants provided written informed consent.
The New Hampshire Birth Cohort Study
To be eligible for the New Hampshire Birth Cohort Study, women were: (i) currently pregnant, (ii) 18-45 years old, (iii) receiving routine prenatal care at one of the study clinics, (iv) living at residence served by a private water system (e.g., serving o15 households or 25 individuals), (v) residing in the same place since their last menstrual period, using the same water supply, and (vi) not planning to move prior to delivery.
Data and Sample Collection
At the enrolment visit (approximately 24-28 weeks gestation), study participants were asked to complete a prenatal questionnaire about their pregnancy. Participants were also provided with a kit for collecting a sample of their home tap water using a commercially washed, high-density polyethylene bottle that met the Environmental Protection Agency's water collection standards. Water samples were stored at − 20˚C or lower until analysis. Tap water samples were analyzed for total arsenic concentration by ICP-MS using an Agilent 7700x (Santa Clara, CA, USA). The detection limit for arsenic in water ranged from 0.009 to 0.074 μg/l and 96% of water samples exceeded the detection limit.
Maternal Urine
At enrollment, participants were asked to provide a urine sample. Samples were analyzed at the University of Arizona using high performance liquid chromatography interfaced with ICP-MS to detect arsenate, arsenite, monomethylarsonic acid, dimethylarsinic acid and arsenobetaine. Detection limits for all species in urine ranged from 0.10 to 0.15 μg/l. The total arsenic concentration used in statistical analysis is the sum of arsenate, arsenite, monomethylarsonic acid and dimethylarsinic acid, and excludes arsenobetaine, an unmetabolized form of arsenic that is considered non-toxic. Urinary creatinine was determined using Cayman's Creatinine Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA).
Placenta
Placental biopsies were uniformly collected from the fetal side, at the base of the cord insertion avoiding vasculature, and measured approximately 1-cm deep and approximately 1-2 cm in diameter. The maternal decidua was removed to avoid inclusion of calcium (Ca) deposits and connective tissue. Biopsies were placed in metal-free tubes and stored at − 80˚C until analysis.
Prior to analysis, samples were transferred to a − 20˚C freezer, then to 4˚C for a maximum of 2 days, and lastly to room temperature. One milliliter of HNO 3 /HCl at 9:1 ratio (Optima™) was added to samples with of up to 500 mg mass, and 2 ml of was added to samples greater than 500 mg. Samples were digested via microwave (CEM, Microwave-Assisted Reaction System), ramping the temperature to 95˚C in 15 min, and holding at this temperature for 45 min. H 2 O 2 (0.25-0.35 ml) was added to each tube and the microwave digestion sequence was repeated. Quality control procedures for this study included the use of a laboratory-made reference placental digest and internal standards. For the placental reference digest, deidentified placental tissue was subsampled to aliquots at the midpoint of the sample weight range, subject to the open-vessel digestion, and then pooled. The pooled sample was mixed, analyzed and an aliquot was included with each batch of placental samples analyzed. Arsenic was analyzed by ICP-MS using He as a collision gas on the Agilent 7700x. NIST 1566b Oyster Tissue was digested and analyzed as a reference material; recovery was 93 ± 7% (n = 33). Analysis of batches of placental tissues routinely used internal standards, initial calibration verification, initial calibration blanks continuing, calibration verification and analytical duplicates and spikes. The detection limit for arsenic in placenta was 0.0148 ng/g.
Maternal and Infant Nails
At 2 weeks postpartum, participants received an information packet requesting maternal and infant toenail clippings within 8 weeks of birth, a timing which was consistent with other studies. 17, 18 Maternal toenails underwent an additional washing procedure that included manual removal of visible dirt and five washes in an ultrasonic bath using Triton X-100 (LabChem, PA, USA) and acetone followed by deionized water, and allowed to dry. All toenail samples were subject to low-pressure microwave digestion using the method outlined above for placenta digestions and were analyzed via ICP-MS. The detection limit differs on a sample-bysample basis because of the difference in sample weights used for digestion and analysis. The detection limit of arsenic in maternal toenails ranged from 0.001 to 0.41 μg/g and for infant toenails ranged from 0.005 to 2.5 μg/g. The detection limit differs on a sample-by-sample basis because of the difference in sample weights used for digestion and analysis. The high maximum value was due to the very low mass of some of the infant toenails.
Statistical Analysis
We used Spearman's correlation coefficients to evaluate relationships between placenta arsenic and maternal and infant biomarkers, and between placenta arsenic and household water arsenic concentrations. We further used linear regression, and to improve model fit and normalize residuals, all arsenic biomarker variables (arsenic concentration in maternal urine, maternal toenails, infant toenails and placenta arsenic concentrations) were log 10 -transformed. All parameter estimates were exponentiated (10 β for covariates and 2 β for dependent variables) representing the percent change in the covariates, and a doubling in the dependent variables, respectively. We examined a variety of potential confounders such as maternal age upon enrollment, pre-pregnancy maternal body mass index, maternal smoking status, infant sex, birth weight and season of toenail collection. We assessed covariates individually in univariate associations with placental arsenic concentration as well on other exposure measures of interest. We used a one-way analysis of variance test to detect whether the season of tap water collection had any influence on the arsenic concentration (log 10 -transformed). All statistical analyses were conducted in JMP version 11 (The SAS Institute, Cary, NC, USA). Participants for whom data were missing, for example, in the analysis of infant toenail arsenic (N = 153), were excluded from our regression models and Spearman's correlations.
RESULTS

Descriptive Characteristics of the Cohort
At the time of this study, the total number of NHBCS participants was 1033. The number of participants providing infant toenail clippings was 153. The characteristics of this group of participants did not differ from those presented in Table 1 . The study population was predominantly white, with an average age of 31.3 and a mean body mass index of 25.3 kg/m 2 (10th-90th percentile range of 20.0-32.1), primarily full term pregnancies (437 weeks) with an equal male/female distribution and an average birthweight of 3455 g (± SD 519) ( Table 1 ). Median arsenic concentrations were 78 (SD = 81) ng/g (N = 579) for maternal toenail arsenic, 68 (SD = 253) ng/g for infant toenail arsenic concentrations (N = 153), 3.62 (SD = 14.7) μg/l for maternal urinary total arsenic (the sum of inorganic and organic species, excluding arsenobetaine) (N = 623), and 0.38 (SD = 11.9) μg/l for household drinking water arsenic concentrations (N = 716). We used a oneway analysis of variance test to detect any influence of the season of tap water collection on the arsenic concentration. Data for arsenic concentration of household tap water were not normally distributed and were log 10 -transformed. This analysis showed that season of collection does not significantly influence household tap water arsenic concentration (F ratio 0.7526, P value 0.5211). Season of collection was unrelated to household drinking water arsenic concentration (ANOVA F ratio 0.7526, P value 0.5211). Arsenic in Arsenic in placenta maternal urine was predominantly present in the organic form dimethylarsinic acid (mean 80.8% SD = 11.9%), with an average of 9.1% monomethylarsonic acid (SD = 6.4%). Inorganic arsenic constituted the remaining 10.1% of urinary arsenic, with on average 5.9% arsenite (SD = 4.7%) and 4.1% arsenate (SD = 7.5%). In the current subgroup of the NHBCS, 9% of participants' household drinking water exceeded the EPA's MCL for arsenic of 10 μg/l. Placenta arsenic concentrations did not differ significantly across the selected maternal and infant characteristics, which included maternal age, pre-pregnancy body mass index, smoking status, parity, infant sex or low birth weight (o 2500 g). Placenta arsenic concentrations ranged from below detection limits (0.0148 ng/g) to 18.35 ng/g (Table 1) , with a median of 0.76 ng/g and an interquartile range of 0.83 ng/g.
Correlations Between Arsenic in Placenta, Maternal and Infant Biomarkers and Tap Water
Positive correlations were observed with placental arsenic and maternal postpartum toenail, maternal gestational urine and infant urine (Figure 1 ). In our regression models, a doubling of arsenic concentration in maternal urine, maternal toenail and infant toenails was associated with 31.0%, 13.2% and 18.9% increases in placental arsenic concentrations, respectively ( Table 2 ). The regression model between placenta arsenic and maternal urinary arsenic concentrations was adjusted for urinary creatinine concentration, but urinary arsenic levels are expressed as μg/l throughout to remain comparable with prior work. 19, 20 Placental arsenic concentrations also were positively associated with measured household water arsenic concentrations ( Table 2 ). For this model, none of the covariates appreciably altered the parameter estimate, and therefore were not adjusted for in the analysis. This model predicted that for a 1 μg/l increase in household water arsenic concentration, placental arsenic increased by 2.1%.
DISCUSSION
Within the NHBCS, total urinary arsenic and toenail arsenic concentrations have been shown previously to correlate with the arsenic concentration of household drinking water, 21, 22 and with the consumption of certain dietary items known to contain elevated concentrations of arsenic. 17, 19, 20 The arsenic biomarkers reported in this study, in addition to placenta, mirror previous findings. When participants are grouped into those with household drinking water either below or above the MCA for arsenic (10 μg/l), there is a significant difference between the arsenic concentrations measured in maternal urine, maternal toenails and placenta ( Supplementary Table 1 ). These differences are less Figure 1 . Pairwise correlations between log 10 -transformed placenta arsenic concentration and log 10 -transformed maternal and infant biomarkers, and arsenic concentration of household drink water. On each panel, the line of fit is shown with 95% confidence intervals, and results of Spearman's correlation (r s ) and P value are shown. pronounced for infant toenail arsenic concentration, but this may be a result of the smaller number of infant toenails that were available for our analysis. We detected correlations between the concentration of arsenic in placental tissue and that of both maternal and infant biomarkers. Further, the arsenic burden of the placenta was related to the concentration of arsenic in household drinking water.
To date, only a small number of studies have measured concentrations of arsenic in placenta (summarized in Table 3 ). 16, [23] [24] [25] [26] [27] [28] [29] Placental arsenic concentrations reported worldwide between 1976 and 2000 30 were on average 6 ng/g (range: 3-12 ng/g) (wet weight). More recently, Jin et al. 24 measured placental arsenic concentrations as part of a study of neural tube defects in a rural area of the Shanxi Province in northern China. Among controls, placenta arsenic concentrations were 11.8 ( ± SD 7.9) ng/g on average (N = 80). In a smaller study of arsenic concentrations in placental tissue from participants living close to a copper smelter in Bulgaria, 28 mean arsenic concentrations of 23 ( ± SD 21) ng/g were detected in placentas of participants living near the smelter (n = 30), whereas an average of 7 ( ± SD 4) ng/g arsenic was measured in placental samples from those outside of the smelter area (N = 15). Previous studies have been hindered by instrumental detection limits, 23, 29 whereas we had the advantage of using ICP-MS for ultra-trace arsenic detection. In light of our low detection limits and our findings of a range of placenta arsenic concentrations that extend below levels previously reported upwards to levels reported in industrially exposed communities, our study presents new information.
Of the prior investigations of placental arsenic, none to our knowledge have directly compared placenta arsenic levels with those measured in other biomarkers. Tabacova et al. 28 estimated that 34% of the variation in placental arsenic could be explained by the participants' place of residence relative to a copper smelter area in Bulgaria. Those living closest to the smelter had a fourfold higher placental arsenic concentration than those living in a nonsmelter area. Concha et al. 16 reported placental arsenic levels from a group exposed to drinking water containing ≈ 200 μg/l arsenic (34 ng/g dry weight) compared with the non-exposed group (7 ng/g dry weight) previously reported in the study by Tabacova et al. 28 However, they were unable to compute correlations between placental arsenic and other biomarkers. In addition to correlations with infant and maternal biomarkers, we found drinking water to be a source of arsenic exposure in our study population that is reflected placental arsenic concentrations.
The limitations of our study included the relatively small number of infant toenail samples, which reduced the precision of our analysis. Although we only had toenail arsenic concentration for 153 infants, the association with placenta data was statistically significant. Additionally, comparison of the selected characteristics of our study cohort (Table 1) with those for whom infant toenail arsenic data were available showed no significant differences. The collection of infant toenails 8 weeks after birth may also raise concerns that postnatal arsenic exposure is reflected in addition to in utero exposure. However, given the slow rate of infant nail growth (estimated to be between 1 and 3 mm per month 31 ), it is unlikely that postnatal nail growth would have reached the distal nail edge at the time of sampling. 31 Nail growth arises from the proximal end of the nail, under the epidermis; whereas it is the free margin at the distal end of the nail that is sampled.
The collection of a single water sample for arsenic determination from study participants may also be viewed as a limitation in the light of recent studies on temporal variability in well water arsenic concentrations, 32 but our early study of reproducibility of sequential water samples suggests this is not an issue. 33 In conclusion, we found positive associations between placental arsenic concentration and both maternal and infant biomarker concentrations as well as household drinking water arsenic concentration. These data suggest inter-marker reliability between our placental arsenic measurements and arsenic measurements from urine and toenails. Although the magnitude of the correlations were relatively low (o 0.2), placenta still may have value as a biomarker of maternal and infant exposures, and be particularly important when considering molecular effects on the placenta as it provides an opportunity to link a biomarker of exposure and biomarker of effect (e.g., changes in gene expression or DNA methylation alterations) in the same functional tissue sample. Arsenic in placenta
